Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Jonathan Riess, Eric B. Haura, Rona Yaeger, Melissa Johnson, Jia Luo, Aparna R. Parikh, Douglas Orr, Salman R. Punekar, Kyriakos Papadopoulos, John H. Strickler, John Powderly, Judy S. Wang, Patricia LoRusso, Alexander Spira, Maria Filippou-Frye, Hina Patel, Satwant Lally, Michelle Yang, David S. Hong, Kathryn C. Arbour
Institutions: UC Davis Comprehensive Cancer Center, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, Sarah Cannon, Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, South Texas Accelerated Research Therapeutics, Duke Cancer Institute, Carolina BioOncology Institute, Florida Cancer Specialists & Research Institute, Yale University, Virginia Cancer Specialists, Revolution Medicines (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7161307704